News EU approval for new asthma drug Exdensur lifts GSK EU approval takes GSK a step closer to fulfilling its blockbuster sales hopes for new long-acting respiratory drug Exdensur.
News UK, US approve GSK's twice-yearly asthma drug GSK scores a first approval in the UK for new severe asthma and CRSwNP therapy Exdensur, but a second in the US covers the asthma indication only.
News GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.
News Amgen, AZ's Tezspire challenges Dupixent in nasal polyps Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.
News Stopwatch starts on reviews of GSK's long-acting asthma drug Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.
News GSK asthma hope depemokimab works in second indication GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
